GleamWall
中文EN

IMA ImageneBio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1835579 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-0.2%
TTM EPS YoY83.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-32.3%
ROA-28.6%
ROIC (approx.)-98.2%
Asset turnover—

Leverage & solvency

Liabilities / assets10.1%
Debt / equity0.00x
Current ratio16.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0$800,000$0
R&D expense$11.27M$6.67M$5.96M$3.27M$15.16M$5.65M$4.04M$3.76M
SG&A expense$6.04M$5.12M$6.12M$5.23M$11.04M$1.71M$2.75M$2.38M
Operating income-$17.31M-$11.78M-$12.08M-$8.50M-$26.19M-$7.36M-$6.00M-$6.14M
Pretax income-$15.60M-$10.16M-$10.61M-$7.18M-$24.85M-$7.58M-$6.08M-$4.80M
Income tax$20,000$16,000$10,000-$276,000-$74,000$15,000$28,000$13,000
Net income-$15.62M-$10.18M-$10.62M-$6.91M-$24.78M-$7.58M-$6.08M-$4.81M
EBITDA-$17.31M-$11.78M-$12.08M-$8.11M-$26.36M-$7.36M-$5.99M-$6.16M
EPS (basic)-0.91-0.63-0.95—-2.91-4.46-3.80—
EPS (diluted)-0.91-0.63-0.95—-2.91-4.46-3.80—
Weighted avg. shares (diluted)17.12M16.16M11.21M—8.80M2.41M2.40M—
Balance sheet
Cash & equivalents$84.85M$94.68M$76.05M$94.53M$103.16M$6.02M$4.92M$12.12M
Short-term investments$41.74M$41.48M$41.16M$40.82M$39.42M$37.35M$77.29M$0
Current assets$130.60M$141.11M$122.01M$140.29M$147.53M$99.01M$117.00M$12.47M
PP&E, net———$0$1,000$419,000$506,000$8,000
Total assets$142.54M$152.04M$136.68M$152.98M$160.88M$126.17M$130.84M$15.92M
Current liabilities$8.07M$6.57M$6.63M$11.23M$11.14M$7.32M$8.79M$17.21M
Short-term debt———$0$0——$7.50M
Total liabilities$14.40M$9.97M$13.36M$19.84M$21.05M$10.26M$12.59M$17.45M
Shareholders' equity$128.14M$142.07M$123.33M$133.14M$139.83M-$180.35M-$169.60M-$160.56M
Shares outstanding—————48.26M48.26M48.26M
Cash flow statement
Operating cash flow-$9.52M-$9.07M-$14.80M-$7.22M-$26.64M-$11.90M-$7.23M-$3.48M
Investing cash flow-$385,000-$346,000-$440,000-$1.36M-$37.33M$0$0$103,000
Financing cash flow$82,000$28.05M-$3.24M$0$122.42M$13.02M$27,000$6.91M
Depreciation & amortization$0$0$0$394,000-$168,000$2,000$2,000-$19,000
Stock-based compensation$1.67M$911,000$876,000$51,000$15.28M$0$57,000$0

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.